A Message from Publisher and CEO Ted Slafsky: We recently welcomed FQHC 340B Compliances Services to our growing list of sponsors. In today’s sponsored content article, FQHC 340B Lead Consultant Michael Gonzalez offers five great tips on how covered entities can
…Category: Pharma Industry
A note from Publisher and CEO Ted Slafsky: Our sponsors are 340B’s industry leaders and we are proud to showcase their innovative solutions and guidance to help you implement and comply with this complex program. Click on the button
…A note from 340B Report CEO and Publisher Ted Slafsky: Please join us in welcoming Comprehensive Pharmacy Services to our growing group of 340B Report sponsors! And I hope you enjoy a new column from
…A note from 340B Report CEO and Publisher Ted Slafsky: I encourage all of you to read Trellis Rx Chief Pharmacy Officer Jerry Buller’s great article in today’s issue about how 340B health systems can leverage
…
DOJ Says Mallinckrodt Owes Medicaid Hundreds of Millions in Rebates, but Is Silent About 340B Overcharges
The U.S. Justice Department is suing drug manufacturer Mallinckrodt for allegedly
…
340B Providers Could Face Drug Access Challenges Due to Coronavirus
In theory, federal law and 340B program guidance should protect 340B entities from shouldering an unfair
…Drug manufacturers are doing a better job of providing the Health Resources and Services Administration (HRSA) with timely and accurate data needed to verify their 340B ceiling prices, the head of the federal 340B drug pricing program indicated today. Nonetheless,
…President Expected to Address Drug Prices in State of the Union Message
In his State of the Union address tonight, President Trump is expected to announce an initiative to make insulin more affordable and to challenge Congress to pass legislation
…Breaking News
BREAKING: Drugmaker Xspire Owes 340B Refunds
Greetings
Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news.
BREAKING: Drugmaker Xspire Owes 340B Refunds
Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds
…